The Food and Drug Administration grants Roche breakthrough therapy designation for its drug venetoclax. The drug is used for the treatment of chronic lymphocytic leukemia (CLL).
FDA Gives Roche Breakthrough Therapy Designation For Venetoclax CLL Treatment
Tech Times - 7 May 2015 15:12
The Food and Drug Administration grants Roche breakthrough therapy designation for its drug venetoclax. The drug is used for the treatment of chronic lymphocytic leukemia (CLL).
Share this Article
Recommended